No products in the cart.
Pre-made Lirilumab benchmark antibody ( Whole mAb, anti-KIRD2 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-316
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Lirilumab biosimilar, Whole Mab: Anti-KIRD2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It binds to KIR2DL1/2L3.
| Products Name (INN Index) | Pre-Made Lirilumab biosimilar, Whole Mab: Anti-KIRD2 therapeutic antibody |
|---|---|
| INN Name | Lirilumab |
| Target | KIRD2 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2012 |
| Year Recommended | 2013 |
| Companies | Novo Nordisk,Bristol-Myers Squibb,Dana-Farber Cancer Institute,Innate Pharma,National Cancer Institute (USA),Ono Pharmaceutical,PrECOG,University of Texas M. D. Anderson Cancer Center |
| Conditions Approved | NA |
| Conditions Active | Chronic lymphocytic leukaemia,Head and neck cancer,Myelodysplastic syndromes,Solid tumours,Bladder cancer |
| Conditions Discontinued | Acute myeloid leukaemia,Hepatitis C,Haematological malignancies,Multiple myeloma,Lymphoma |
| Development Tech | Medarex UltiMAb Mouse |
| Previous Name | NA |
| Gm Offical Target Name | KIRD2 |
| Package |
Previous slide
Next slide
